Foundation Medicine and PMV Pharma Partner to Develop Genomic Profiling for TP53 Mutation Therapy, Targets TP53 Mutation in Advanced Cancers with Investigational Therapy Rezatapopt
Portfolio Pulse from Benzinga Newsdesk
Foundation Medicine and PMV Pharmaceuticals have partnered to develop a genomic profiling test as a companion diagnostic for PMV Pharma's investigational therapy, rezatapopt, targeting TP53 Y220C mutations in advanced cancers.
May 29, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PMV Pharmaceuticals has partnered with Foundation Medicine to develop a genomic profiling test for its investigational therapy, rezatapopt, targeting TP53 Y220C mutations in advanced cancers.
The partnership with Foundation Medicine to develop a companion diagnostic for rezatapopt could accelerate the development and potential approval of PMV Pharma's investigational therapy, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100